Research programme: anticancer antibodies - Cancer Research UK/MedImmuneAlternative Names: 264RAD; Cancer therapeutics - Cancer Research UK/MedImmune
Latest Information Update: 09 Jul 2016
At a glance
- Originator Cancer Research UK; MedImmune
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Pancreatic cancer